source
- Inhibrx says combo therapy shrank more tumors than Merck's Keytruda aloneSan Diego-based biotech Inhibrx is claiming that it outperformed Merck’s Keytruda in a difficult-to-treat cancer. The combination of Keytruda and Inhibrx’s experimental drug INBRX-106 shrank more t…Endpoints · 3mo ago↗ source
- STAT+: Astellas treatment offers new hope to a devastated rare disease communityAlzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The ReadoutSTAT · 3mo ago↗ source
- Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trialInhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.